David J. Chang

Chief Medical Officer at Cabaletta Bio

Dr. Chang joined Cabaletta in June 2019 as Chief Medical Officer. Previously, he was Senior Vice President and Head, Inflammation, Autoimmunity & Neuroscience, or IA&NS, Global Medicines Development at AstraZeneca Pharmaceuticals LP, where he oversaw development projects of both biologics and small molecules in a variety of indications and led the late-stage clinical development organization for IA&NS. Prior to AstraZeneca, Dr. Chang served in various positions at GlaxoSmithKline plc, including VP and Head, Immuno-Inflammation, Clinical Development. Dr. Chang is an adjunct associate professor in the Division of Rheumatology at the Perelman School of Medicine of the University of Pennsylvania. He received his M.D. from New York University School of Medicine, his M.P.H. from Emory University, and his B.S. from Yale University. Dr. Chang completed his internship and residency in internal medicine at the New York Hospital—Cornell University Medical Center and a fellowship in Rheumatology at the Hospital for Special Surgery—Cornell University Medical Center.

Location

Philadelphia, United States

Links


Org chart

No direct reports

Teams


Offices


Cabaletta Bio

2 followers

Cabaletta Bio discovers and develops targeted cell therapy product candidates to potentially cure patients with autoimmune diseases.


Industries

Employees

51-200

Links